NGNE Neurogene Inc.
Healthcare$27.10-2.20%ClosedMarket Cap: $428.2M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.60
P/S
0.00
EV/EBITDA
-3.21
DCF Value
$4.36
FCF Yield
-18.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-37.9%
ROA
-37.5%
ROIC
-44.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-33.3M | $-30.9M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-27.5M | $-24.7M | $— | — |
| FY null | $0.00 | -Infinity% | $-103.2M | $-90.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-23.8M | $-21.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-26.1M | $-22.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-25.9M | $-22.6M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-21.5M | $-19.5M | $— | — |
| FY null | $925.0K | -251.0% | $-82.6M | $-75.1M | $— | — |
| Q3 null | $0.00 | NaN% | $-22.2M | $-20.2M | $— | — |
| Q2 null | $925.0K | 11.7% | $-20.1M | $-18.5M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-18.8M | $-16.9M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-14.7M | $2.4M | $-1.21 | — |